Study title: Long-term safety and efficay of Actimmune therapy in young children with chronic granulomatous disease (CGD): An integrated summary of data extracted from Studies I0016g, I0016g(A),I0034g, and I0286n in children initiating Actimmune therapy prior to 1 year of age and prior to 3 years of age, respectively.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Immune System Diseases [C20] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: INTERFERON GAMMA (1B) | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: 1941, GCGD4-001 U04-0035 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | Y | Y | - |